Karlsen, T. H., Folseraas, T., Thorburn, D. & Vesterhus, M. Primary sclerosing cholangitis–a comprehensive review. J. Hepatol. 67, 1298–1323 (2017).
Weismuller, T. J. et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 152, 1975–1984 (2017).
Boonstra, K. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58, 2045–2055 (2013).
Karlsen, T. H., Schrumpf, E. & Boberg, K. M. Update on primary sclerosing cholangitis. Dig. Liver Dis. 42, 390–400 (2010).
Jiang, X. & Karlsen, T. H. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat. Rev. Gastroenterol. Hepatol. 14, 279–295 (2017).
Ji, S. G. et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat. Genet. 49, 269–273 (2017).
Liu, J. Z. et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat. Genet. 45, 670–675 (2013). Key study delineating the autoimmune genetic architecture of PSC.
CAS PubMed PubMed Central Google Scholar
Peng, X. et al. Immunosuppressive agents for the treatment of primary sclerosing cholangitis: a systematic review and meta-analysis. Dig. Dis. 35, 478–485 (2017).
Albillos, A., de Gottardi, A. & Rescigno, M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J. Hepatol. 72, 558–577 (2020).
Iliev, I. D. & Cadwell, K. Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases. Gastroenterology 160, 1050–1066 (2021).
Sokol, H. et al. Fungal microbiota dysbiosis in IBD. Gut 66, 1039–1048 (2017).
de Vries, E. et al. Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma. Liver Int. 40, 3042–3050 (2020).
Mouchli, M. A. et al. Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Inflamm. Bowel Dis. 24, 1074–1081 (2018).
PubMed PubMed Central Google Scholar
Lunder, A. K. et al. Prevalence of sclerosing cholangitis, detected by magnetic resonance cholangiography, in patients with long-term inflammatory bowel disease. Gastroenterology 151, 660–669 (2016). First study to show that the prevalence of sclerosing cholangitis-like changes on MRC are more common than clinically overt PSC.
Broome, U. & Bergquist, A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis. 26, 31–41 (2006).
Marelli, L. et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 60, 1224–1228 (2011).
Navaneethan, U. et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 10, 540–546 (2012).
Boden, R. W., Rankin, J. G., Goulston, S. J. & Morrow, W. The liver in ulcerative colitis: the significance of raised serum-alkaline-phosphatase levels. Lancet 2, 245–248 (1959).
Rankin, J. G., Boden, R. W., Goulston, S. J. & Morrow, W. The liver in ulcerative colitis; treatment of pericholangitis with tetracycline. Lancet 2, 1110–1112 (1959).
Farkkila, M. et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40, 1379–1386 (2004). First randomized clinical trial of antibiotics in PSC.
Tabibian, J. H. et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis–a pilot study. Aliment. Pharmacol. Ther. 37, 604–612 (2013).
Cangemi, J. R. et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96, 790–794 (1989).
Martin, F. M. et al. Surgical aspects of sclerosing cholangitis. Results in 178 patients. Ann. Surg. 212, 551–556 (1990).
CAS PubMed PubMed Central Google Scholar
Nordenvall, C. et al. Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients. Aliment. Pharmacol. Ther. 47, 238–245 (2018).
Vera, A. et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 360, 1943–1944 (2002).
Graziadei, I. W. et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29, 1050–1056 (1999).
Steenstraten, I. C. et al. Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Aliment. Pharmacol. Ther. 49, 636–643 (2019).
PubMed PubMed Central Google Scholar
Peverelle, M., Paleri, S., Hughes, J., De Cruz, P. & Gow, P. J. Activity of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis predicts poorer clinical outcomes. Inflamm. Bowel Dis. 26, 1901–1908 (2020).
Trivedi, P. J. et al. The impact of ileal pouch–anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 48, 322–332 (2018).
Davies, Y. K. et al. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep. Transpl. 2013, 314292 (2013).
Hey, P., Lokan, J., Johnson, P. & Gow, P. Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. BMJ Case Rep. 2017, bcr2017221165 (2017).
Devkota, S. et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10−/− mice. Nature 487, 104–108 (2012).
CAS PubMed PubMed Central Google Scholar
Schwartz, D. J., Langdon, A. E. & Dantas, G. Understanding the impact of antibiotic perturbation on the human microbiome. Genome Med. 12, 82 (2020).
PubMed PubMed Central Google Scholar
Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59–64 (2014).
Acharya, C. & Bajaj, J. S. Chronic liver diseases and the microbiome — translating our knowledge of gut microbiota to management of chronic liver disease. Gastroenterology 160, 556–572 (2021).
Wang, J. et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat. Genet. 48, 1396–1406 (2016).
CAS PubMed PubMed Central Google Scholar
Ruhlemann, M. C. et al. Genome-wide association study in 8,956 German individuals identifies influence of ABO histo-blood groups on gut microbiome. Nat. Genet. 53, 147–155 (2021).
Lopera-Maya, E. A. et al. Effect of host genetics on the gut microbiome in 7738 participants of the Dutch Microbiome Project. Nat. Genet. 54, 143–151 (2022).
Qin, Y. et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat. Genet. 54, 134–142 (2022).
Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15, 382–392 (2014).
CAS PubMed PubMed Central Google Scholar
Xu, Z. & Knight, R. Dietary effects on human gut microbiome diversity. Br. J. Nutr. 113 (Suppl.), 1–5 (2015).
Vujkovic-Cvijin, I. et al. Host variables confound gut microbiota studies of human disease. Nature 587, 448–454 (2020).
CAS PubMed PubMed Central Google Scholar
Yap, C. X. et al. Autism-related dietary preferences mediate autism–gut microbiome associations. Cell 184, 5916–5931 (2021). Key study in highlighting the importance of confounding factors in assessing dietary impact on the gut microbiome.
de Vries, E. M. et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study. Hepatology 65, 907–919 (2017).
Mazhar, A. & Russo, M. W. Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 53, 774–783 (2021).
Fairfield, B. & Schnabl, B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 3, 100220 (2021).
Aron-Wisnewsky, J. et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat. Rev. Gastroenterol. Hepatol. 17, 279–297 (2020).
Iwasawa, K. et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis. Gut 66, 1344–1346 (2016).
留言 (0)